SCHEMBL13764772

SCHEMBL13764772

C[C@@H](c1ccccc1)N1C[C@@](C)(C(=O)OC(C)(C)C)C(O)C1=O

nearest known ligand 0.43

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.43
HSD11B1 P28845 1/20 0.38
GAA P10253 2/20 0.38
MAPK1 P28482 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
ATM Q13315 1/20 0.35
ALDH1A1 P00352 2/20 0.35
HPGD P15428 1/20 0.34
GLA P06280 1/20 0.34
CYP2C9 P11712 1/20 0.34
HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3977726 1.00 KMT2A (0.43) KMT2AHSD11B1GAAMAPK1SMN1; SMN2
SCHEMBL3974988 1.00 KMT2A (0.43) KMT2AHSD11B1GAAMAPK1SMN1; SMN2
SCHEMBL3976509 0.87 KMT2A (0.43) KMT2AHSD11B1GAAMAPK1SMN1; SMN2
SCHEMBL9939516 0.85 KMT2A (0.41) KMT2AHSD11B1GAAMAPK1SMN1; SMN2
SCHEMBL4181294 0.84 KMT2A (0.47) KMT2AHSD11B1GAAMAPK1ALDH1A1
SCHEMBL4190391 0.84 KMT2A (0.47) KMT2AHSD11B1GAAMAPK1ALDH1A1
SCHEMBL762310 0.84 KMT2A (0.40) KMT2AHSD11B1GAAMAPK1SMN1; SMN2
SCHEMBL761862 0.84 KMT2A (0.40) KMT2AHSD11B1GAAMAPK1SMN1; SMN2
SCHEMBL13021387 0.83 KMT2A (0.39) KMT2AHSD11B1GAAMAPK1SMN1; SMN2
SCHEMBL2670516 0.80 KMT2A (0.40) KMT2AHSD11B1GAAMAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7563805-B2 7-[3-Amino-3,4-dimethylpyrrolidine-1-yl]-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-1,4-dihydro-8-methyl-4-oxoquinoline-3-carboxylic acid: quinoline bactericide; broad spectrum, strong antibacterial activity for Grampositive/-negative including multiple resistant cocci; side effect reductcion; drug design DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2009-07-21 US disclosed